Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by DrHolidayon Jul 16, 2018 7:10pm
110 Views
Post# 28324108

RE:RE:A monster in the making 3 billion products lined up

RE:RE:A monster in the making 3 billion products lined up
allain250 wrote: iCo-007 may also have a potential for treatment of certain oncology indications, including ovarian cancer. 007 is nearing completion of Phase 1. Because of the nature of ongoing tests iCo has had hints of what might be seen in Phase Two trials, Confidence, as a result of early trials, is very high. The next step is to either partner develop the compound or raise sufficient capital to enter into Phase II trials. iCo-008 - Severe Ocular Allergies ~$100M+. - 008 is ready for Phase 2 in vernal keratoconjunctivitis (“VKC”). The next step is to partner compound for VKC or potentially another disease (such as asthma, which has a similar underlying disease biology). If iCo partners for a different disease than VKC, some additional pre-clinical work would be required. iCo-009 - Fungal & Parasitic Infections ~$1B+. Also represents a new drug delivery technology with the potential to reprofile other IV administered drugs to the oral route of administration. AmpB works, its been around since the fifties and is the standard against which all other drugs in this class are measured. The problem with the drug is how it was delivered. It now seems a self-administered (no hospital stay, no toxicity issues), oral formulation of AmpB is attainable. 009 is late pre-clinical stage. The next steps are to complete preclinical toxicology studies and then launch a Phase 1 safety trials

This hypocrite has suddenly turned bearish after being so very bullish. If allain250 is working for a brokerage house, then his activities on this bullboard need to be investigated by IROC so they can suspend or revoke his license to sell securities. It appears that the timeliness of his bullish calls coincides with any upswings in trading so that he can capitalize by selling on strength, and then go short and turn bearish with negative posts designed to undermine confidence in the prospects for ICO. This type of boiler room operation is illegal in my opinion and this is a serious violation of securities law. So, allain250 could be forced to disgorge any trading profits and be suspended along with beng fined. ICO management should definitely lodge a complaint against him with the securities commission. Today's shorting activity was designed to hit all the stop loss orders while there was a concerted effort by certain posters to bash.


DOC.

<< Previous
Bullboard Posts
Next >>